Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 151543, 5 pages
http://dx.doi.org/10.1155/2014/151543
Review Article

Quinolone-Containing Therapies in the Eradication of Helicobacter pylori

1Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123, Ta-Pei Road, Niao-Sung District, Kaohsiung 833, Taiwan
2Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123, Ta-Pei Road, Niao-Sung District, Kaohsiung 833, Taiwan

Received 2 July 2014; Accepted 8 August 2014; Published 28 August 2014

Academic Editor: Deng-Chyang Wu

Copyright © 2014 Seng-Kee Chuah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Matsumoto, I. Miki, N. Aoyama et al., “Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan,” Digestive and Liver Disease, vol. 37, no. 11, pp. 821–825, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. S. K. Chuah, F. W. Tsay, P. I. Hsu, and D. C. Wu, “A new look at anti-Helicobacter pylori therapy,” World Journal of Gastroenterology, vol. 17, no. 35, pp. 3971–3975, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. W. D. Chey and B. C. Y. Wong, “American College of Gastroenterology guideline on the management of Helicobacter pylori infection,” The American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. K. M. Fock, P. Katelaris, K. Sugano et al., “Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection,” Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1587–1600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence consensus report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S. K. Chuah, P. I. Hsu, K. C. Chang et al., “Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori,” Helicobacter, vol. 17, no. 3, pp. 216–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. S. K. Chuah, W. C. Tai, P. I. Hsu et al., “The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-days' levofloxacin/amoxicillin/protonpump inhibitors—a pilot study,” Helicobacter, vol. 17, pp. 374–381, 2012. View at Google Scholar
  8. A. de Sarro and G. de Sarro, “Adverse reactions to fluoroquinolones: an overview on mechanistic aspects,” Current Medicinal Chemistry, vol. 8, no. 4, pp. 371–384, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Tanaka, E. Isogai, H. Isogai et al., “Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 6, pp. 1039–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. K. L. Goh and P. Navaratnam, “High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia,” Helicobacter, vol. 16, no. 3, pp. 241–245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Murakami, T. Furuta, T. Ando et al., “Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan,” Journal of Gastroenterology, vol. 48, no. 10, pp. 1128–1135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Robicsek, G. A. Jacoby, and D. C. Hooper, “The worldwide emergence of plasmid-mediated quinolone resistance,” The Lancet Infectious Diseases, vol. 6, no. 10, pp. 629–640, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Su, Y. Li, H. Li et al., “Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China,” Helicobacter, vol. 18, no. 4, pp. 274–279, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. T. T. Binh, S. Shiota, L. T. Nguyen et al., “The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam,” Journal of Clinical Gastroenterology, vol. 47, no. 3, pp. 233–238, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Rajper, E. Khan, Z. Ahmad, S. M. Z. Alam, A. Akbar, and R. Hasan, “Macrolide and fluoroquinolone resistance in Helicobacter pylori isolates: an experience at a tertiary care centre in Pakistan,” Journal of the Pakistan Medical Association, vol. 62, no. 11, pp. 1140–1144, 2012. View at Google Scholar · View at Scopus
  16. N. Wueppenhorst, H. Stueger, M. Kist, and E. Glocker, “High secondary resistance to quinolones in German Helicobacter pylori clinical isolates,” Journal of Antimicrobial Chemotherapy, vol. 68, no. 7, pp. 1562–1566, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Almeida, J. M. Romãozinho, M. M. Donato et al., “Helicobacter pylori antimicrobial resistance rates in the central region of Portugal,” Clinical Microbiology and Infection, 2014. View at Publisher · View at Google Scholar
  18. A. H. Tveit, M. G. Bruce, D. L. Bruden et al., “Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska native persons from 2000 to 2008,” Journal of Clinical Microbiology, vol. 49, no. 10, pp. 3638–3643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. N. Eisig, F. M. Silva, R. C. Barbuti, T. Navarro-Rodriguez, J. P. P. Moraes-Filho, and J. Pedrazzoli Jr., “Helicobacter pylori antibiotic resistance in Brazil: Clarithromycin is still a good option,” Arquivos de Gastroenterologia, vol. 48, no. 4, pp. 261–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. W. C. Tai, C. H. Lee, and S. S. Chiou, “The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication,” PLoS ONE, vol. 9, no. 8, Article ID e105822, 2014. View at Google Scholar
  21. E. R. Greenberg, G. L. Anderson, D. R. Morgan et al., “14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial,” The Lancet, vol. 378, no. 9790, pp. 507–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Laine, R. Hunt, H. EI-Zimaity, B. Nguyen, M. Osato, and J. Spénard, “Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial,” The American Journal of Gastroenterology, vol. 98, no. 3, pp. 562–567, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Vaira, A. Zullo, N. Vakil et al., “Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial,” Annals of Internal Medicine, vol. 146, no. 8, pp. 556–563, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. J. M. Liou, C. C. Chen, M. J. Chen et al., “Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre , open-label, randomized trial,” The Lancet, vol. 381, pp. 205–213, 2013. View at Google Scholar
  25. A. Zullo, L. Gatta, V. de Francesco et al., “High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 12, pp. 1419–1424, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Seddik, S. Ahid, T. El Adioui et al., “Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study,” European Journal of Clinical Pharmacology, vol. 69, no. 9, pp. 1709–1715, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. K. S. Liu, I. F. Hung, W. K. Seto et al., “Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial,” Gut, vol. 63, no. 9, pp. 1410–1415, 2014. View at Publisher · View at Google Scholar
  28. J. S. Kim, B. W. Kim, J. H. Ham et al., “Sequential therapy for Helicobacter pylori infection in Korea: systematic review and meta-analysis,” Gut Liver, vol. 7, pp. 546–551, 2013. View at Google Scholar
  29. H. Fakheri, T. Taghvaei, V. Hosseini, and Z. Bari, “A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in iran: a randomized clinical trial,” Helicobacter, vol. 17, no. 1, pp. 43–48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Sirimontaporn, D. Thong-Ngam, S. Tumwasorn, and V. Mahachai, “Ten-day sequential therapy of Helicobacter pylori infection in thailand,” The American Journal of Gastroenterology, vol. 105, no. 5, pp. 1071–1075, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. D. C. Wu, P. I. Hsu, J. Y. Wu et al., “Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection,” Clinical Gastroenterology and Hepatology, vol. 8, pp. 36–41, 2010. View at Google Scholar
  32. A. S. Essa, J. R. Kramer, D. Y. Graham, and G. Treiber, “Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication,” Helicobacter, vol. 14, no. 2, pp. 109–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, “Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days,” Helicobacter, vol. 16, no. 2, pp. 139–145, 2011. View at Google Scholar
  34. T. S. Wu, H. M. Hu, F. C. Kuo, and C. H. Kuo, “Eradication of Helicobacter pylori infection,” Kaohsiung Journal of Medical Sciences, vol. 30, pp. 167–172, 2014. View at Google Scholar
  35. M. Berning, S. Krasz, and S. Miehlke, “Review: should quinolones come first in Helicobacter pylori therapy?” Therapeutic Advances in Gastroenterology, vol. 4, no. 2, pp. 103–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. M. C. Peedikayil, F. I. Alsohaibani, and A. H. Alkhenizan, “Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials,” PLoS ONE, vol. 9, no. 1, Article ID e85620, 2014. View at Publisher · View at Google Scholar
  37. S. P. Xiao, M. Gu, and G. X. Zhang, “Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis,” Scandinavian Journal of Gastroenterology, vol. 49, pp. 528–538, 2014. View at Google Scholar
  38. J. Molina-Infante, B. Perez-Gallardo, M. Fernandez-Bermejo et al., “Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 10, pp. 1077–1084, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. J. P. Gisbert and F. De La Morena, “Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 1, pp. 35–44, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Miehlke, S. Krasz, W. Schneider-Brachert et al., “Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection,” Helicobacter, vol. 16, no. 6, pp. 420–426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Cammarota, A. Martino, G. Pirozzi et al., “High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection,” Alimentary Pharmacology & Therapeutics, vol. 19, no. 7, pp. 789–795, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Boyanova, “Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria,” Journal of Medical Microbiology, vol. 58, no. 7, pp. 930–935, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Mégraud and P. Lehours, “Helicobacter pylori detection and antimicrobial susceptibility testing,” Clinical Microbiology Reviews, vol. 20, no. 2, pp. 280–322, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Ierardi, F. Giorgio, G. Losurdo, A. D. Leo, and M. Principi, “As the increase in antibiotic resistances could change the treatment of helicobacter pylori infection: it will be a matter of geography?” World Journal of Gastroenterology, vol. 19, pp. 8168–8180, 2013. View at Google Scholar
  45. J. M. Liou, C. C. Chen, C. Y. Chang et al., “Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial,” Journal of Antimicrobial Chemotherapy, vol. 68, pp. 450–456, 2013. View at Google Scholar
  46. J. Matsuzaki, H. Suzuki, T. Nishizawa et al., “Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 3, pp. 1643–1645, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Schabereiter-Gurtner, A. M. Hirschl, B. Dragosics et al., “Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens,” Journal of Clinical Microbiology, vol. 42, no. 10, pp. 4512–4518, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. J. M. Liou, C. Y. Chang, W. H. Sheng et al., “Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacinand clarithromycin-based therapies,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 3, pp. 1123–1129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Y. Jeon, A. D. Calver, T. C. Victor, R. M. Warren, S. S. Shin, and M. B. Murray, “Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community,” International Journal of Tuberculosis and Lung Disease, vol. 15, no. 1, pp. 77–83, 2011. View at Google Scholar · View at Scopus
  50. R. A. Devasia, A. Blackman, T. Gebretsadik et al., “Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure,” The American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 4, pp. 365–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. W. C. Tai, T. H. Hu, C. H. Lee, H. H. Chen, C. C. Huang, and S. K. Chuah, “Ano-perianal tuberculosis: 15 years of clinical experiences in Southern Taiwan,” Colorectal Disease, vol. 12, no. 7, pp. e114–120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. W. L. Chang, C. Y. Kao, C. T. Wu et al., “Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan,” Helicobacter, vol. 17, no. 3, pp. 210–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Y. Kim, J. Yim, J. S. Park et al., “Clinical effects of gemifloxacin on the delay of tuberculosis treatment,” Journal of Korean Medical Science, vol. 28, no. 3, pp. 378–382, 2013. View at Publisher · View at Google Scholar · View at Scopus